	US 12,029,782 B2
	MHC class II T-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (T1D) and methods of use thereof
Ronald D. Seidel, III, Boston, MA (US); Rodolfo J. Chaparro, Cambridge, MA (US); John F. Ross, Boston, MA (US); and Chee Meng Low, Boston, MA (US)
Assigned to Cue Biopharma, Inc., Boston, MA (US)
Filed by Cue Biopharma, Inc., Boston, MA (US)
Filed on Jul. 6, 2023, as Appl. No. 18/218,943.
Application 18/218,943 is a continuation of application No. 18/107,244, filed on Feb. 8, 2023.
Application 18/107,244 is a continuation of application No. PCT/US2021/049485, filed on Sep. 8, 2021.
Claims priority of provisional application 63/076,310, filed on Sep. 9, 2020.
Prior Publication US 2023/0346900 A1, Nov. 2, 2023
Int. Cl. C07K 14/62 (2006.01); A61K 39/00 (2006.01); A61P 3/10 (2006.01); A61P 37/06 (2006.01); C07K 7/08 (2006.01); C07K 14/495 (2006.01); C07K 14/525 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C12N 9/88 (2006.01)

CPC A61K 39/0008 (2013.01) [A61P 3/10 (2018.01); A61P 37/06 (2018.01); C07K 7/08 (2013.01); C07K 14/495 (2013.01); C07K 14/525 (2013.01); C07K 14/55 (2013.01); C07K 14/62 (2013.01); C07K 14/70532 (2013.01); C07K 14/70539 (2013.01); C12N 9/88 (2013.01); C12Y 401/01015 (2013.01); A61K 2039/577 (2013.01); A61K 2039/605 (2013.01); A61K 2039/645 (2013.01); C07K 2319/30 (2013.01)]

2 Claims

1. A T-cell modulatory multimeric polypeptide (TMMP) that is a homodimer of two heterodimers, wherein each heterodimer comprises a first polypeptide having the amino acid sequence set forth in SEQ ID NO: 185 and a second polypeptide having the amino acid sequence set forth in SEQ ID NO: 186, and wherein the heterodimers are covalently linked to one another through disulfide bonds formed between the Ig Fc polypeptides in the second polypeptide of each heterodimer.